MediWound reports Q3 EPS (98c), consensus (44c)

Reports Q3 revenue $4.355M, consensus $6.01M. “We made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid approval for pediatric use in the U.S.,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “With the upcoming launch of the Phase 3 trial for EscharEx in venous leg ulcers, we’re advancing closer to addressing critical unmet needs in a $2 billion market. Additionally, we will be conducting a head-to-head Phase 2 study vs. collagenase in 2025, to further demonstrate EscharEx’s competitive advantage and maximize its commercial opportunity. We’re also accelerating our diabetic foot ulcer program with Phase 2/3 preparations well underway. Our manufacturing expansion remains on track, positioning us to meet the growing demand for NexoBrid globally.”